A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma

被引:155
作者
Fan, Qiwen [1 ,3 ]
Aksoy, Ozlem [1 ,3 ]
Wong, Robyn A. [1 ,3 ]
Ilkhanizadeh, Shirin [1 ,3 ]
Novotny, Chris J. [2 ]
Gustafson, William C. [3 ,4 ]
Truong, Albert Yi-Que [4 ,5 ]
Cayanan, Geraldine [1 ,3 ]
Simonds, Erin F. [1 ,3 ]
Haas-Kogan, Daphne [6 ]
Phillips, Joanna J. [3 ,5 ]
Nicolaides, Theodore [4 ,5 ]
Okaniwa, Masanori [2 ]
Shokat, Kevan M. [2 ]
Weiss, William A. [1 ,3 ,4 ,5 ]
机构
[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA
[2] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Howard Hughes Med Inst, San Francisco, CA 94158 USA
[3] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA
[4] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94158 USA
[5] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94158 USA
[6] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02215 USA
关键词
GROWTH-FACTOR RECEPTOR; RAPAMYCIN COMPLEX; MAMMALIAN TARGET; MOLECULAR-BASIS; CANCER; ACTIVATION; RESISTANCE; LANDSCAPE; EFFICACY; GLIOMA;
D O I
10.1016/j.ccell.2017.01.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although signaling from phosphatidylinositol 3-kinase (PI3K) and AKT to mechanistic target of rapamycin (mTOR) is prominently dysregulated in high-grade glial brain tumors, blockade of PI3K or AKT minimally affects downstream mTOR activity in glioma. Allosteric mTOR inhibitors, such as rapamycin, incompletely block mTORC1 compared with mTOR kinase inhibitors (TORKi). Here, we compared RapaLink-1, a TORKi linked to rapamycin, with earlier-generation mTOR inhibitors. Compared with rapamycin and Rapalink-1, TORKi showed poor durability. RapaLink-1 associated with FKBP12, an abundant mTOR-interacting protein, enabling accumulation of RapaLink-1. RapaLink-1 showed better efficacy than rapamycin or TORKi, potently blocking cancer-derived, activating mutants of mTOR. Our study re-establishes mTOR as a central target in glioma and traces the failure of existing drugs to incomplete/nondurable inhibition of mTORC1.
引用
收藏
页码:424 / 435
页数:12
相关论文
共 28 条
[1]   The structural basis for mTOR function [J].
Baretic, Domagoj ;
Williams, Roger L. .
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2014, 36 :91-101
[2]  
Bradshaw JM, 2015, NAT CHEM BIOL, V11, P525, DOI [10.1038/nchembio.1817, 10.1038/NCHEMBIO.1817]
[3]   The Somatic Genomic Landscape of Glioblastoma [J].
Brennan, Cameron W. ;
Verhaak, Roel G. W. ;
McKenna, Aaron ;
Campos, Benito ;
Noushmehr, Houtan ;
Salama, Sofie R. ;
Zheng, Siyuan ;
Chakravarty, Debyani ;
Sanborn, J. Zachary ;
Berman, Samuel H. ;
Beroukhim, Rameen ;
Bernard, Brady ;
Wu, Chang-Jiun ;
Genovese, Giannicola ;
Shmulevich, Ilya ;
Barnholtz-Sloan, Jill ;
Zou, Lihua ;
Vegesna, Rahulsimham ;
Shukla, Sachet A. ;
Ciriello, Giovanni ;
Yung, W. K. ;
Zhang, Wei ;
Sougnez, Carrie ;
Mikkelsen, Tom ;
Aldape, Kenneth ;
Bigner, Darell D. ;
Van Meir, Erwin G. ;
Prados, Michael ;
Sloan, Andrew ;
Black, Keith L. ;
Eschbacher, Jennifer ;
Finocchiaro, Gaetano ;
Friedman, William ;
Andrews, David W. ;
Guha, Abhijit ;
Iacocca, Mary ;
O'Neill, Brian P. ;
Foltz, Greg ;
Myers, Jerome ;
Weisenberger, Daniel J. ;
Penny, Robert ;
Kucherlapati, Raju ;
Perou, Charles M. ;
Hayes, D. Neil ;
Gibbs, Richard ;
Marra, Marco ;
Mills, Gordon B. ;
Lander, Eric ;
Spellman, Paul ;
Wilson, Richard .
CELL, 2013, 155 (02) :462-477
[4]   RAPT1, A MAMMALIAN HOMOLOG OF YEAST TOR, INTERACTS WITH THE FKBP12 RAPAMYCIN COMPLEX [J].
CHIU, MI ;
KATZ, H ;
BERLIN, V .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (26) :12574-12578
[5]   Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP [J].
Choi, JW ;
Chen, J ;
Schreiber, SL ;
Clardy, J .
SCIENCE, 1996, 273 (5272) :239-242
[6]   A dual phosphoinositide-3-kinase α/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma [J].
Fan, Qi-Wen ;
Cheng, Christine K. ;
Nicolaides, Theodore P. ;
Hackett, Christopher S. ;
Knight, Zachary A. ;
Shokat, Kevan M. ;
Weiss, William A. .
CANCER RESEARCH, 2007, 67 (17) :7960-7965
[7]   A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma [J].
Fan, Qi-Wen ;
Knight, Zachary A. ;
Goldenberg, David D. ;
Yu, Wei ;
Mostov, Keith E. ;
Stokoe, David ;
Shokat, Kevan M. ;
Weiss, William A. .
CANCER CELL, 2006, 9 (05) :341-349
[8]   EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma [J].
Fan, Qi-Wen ;
Cheng, Christine ;
Knight, Zachary A. ;
Haas-Kogan, Daphne ;
Stokoe, David ;
James, C. David ;
McCormick, Frank ;
Shokat, Kevan M. ;
Weiss, William A. .
SCIENCE SIGNALING, 2009, 2 (55) :ra4
[9]   Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 [J].
Feldman, Morris E. ;
Apsel, Beth ;
Uotila, Aino ;
Loewith, Robbie ;
Knight, Zachary A. ;
Ruggero, Davide ;
Shokat, Kevan M. .
PLOS BIOLOGY, 2009, 7 (02) :371-383
[10]   The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer [J].
Folkes, Adrian J. ;
Ahmadi, Khatereh ;
Alderton, Wendy K. ;
Alix, Sonia ;
Baker, Stewart J. ;
Box, Gary ;
Chuckowree, Irina S. ;
Clarke, Paul A. ;
Depledge, Paul ;
Eccles, Suzanne A. ;
Friedman, Lori S. ;
Hayes, Angela ;
Hancox, Timothy C. ;
Kugendradas, Arumugam ;
Lensun, Letitia ;
Moore, Pauline ;
Olivero, Alan G. ;
Pang, Jodie ;
Patel, Sonal ;
Pergl-Wilson, Giles H. ;
Raynaud, Florence I. ;
Robson, Anthony ;
Saghir, Nahid ;
Salphati, Laurent ;
Sohal, Sukhjit ;
Ultsch, Mark H. ;
Valenti, Melanie ;
Wallweber, Heidi J. A. ;
Wan, Nan Chi ;
Wiesmann, Christian ;
Workman, Paul ;
Zhyvoloup, Alexander ;
Zvelebil, Marketa J. ;
Shuttleworth, Stephen J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (18) :5522-5532